An Optimistic Outlook Prevails for Innovative Biopharma Companies Despite Market & Investor Trends

While most of the funding for biotech startups developing novel therapeutics has stalled in the past year as VCs take a more conservative approach and focus on companies already generating revenue through multiple streams, demand for therapies has not decreased.